prepandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) novartis vaccines and diagnostics
novartis vaccines and diagnostics s.r.l. - influenssa virus pinta-antigeenejä (haemagglutinin ja neuraminidaasin) kanta a, vietnam, 1194, 2004 (h5n1) - influenza, human; immunization; disease outbreaks - rokotteet - aktiivinen immunisaatio influenssa a -viruksen h5n1-alatyypin suhteen. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.
covid-19 vaccine (inactivated, adjuvanted) valneva
valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - rokotteet - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age. the use of this vaccine should be in accordance with official recommendations.
bcg vaccine ajvaccines injektiokuiva-aine ja liuotin, suspensiota varten
aj vaccines a/s - mycobacterium lehmä bcg (tanskalainen kanta 1331), elävä heikennetty - injektiokuiva-aine ja liuotin, suspensiota varten - tuberkuloosirokote
zoonotic influenza vaccine seqirus
seqirus s.r.l. - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - rokotteet - active immunisation against h5 subtype of influenza a virus.
pandemic influenza vaccine h5n1 baxter ag
resilience biomanufacturing ireland limited - influenssa rokote (koko virion, inaktivoitu) sisältävät antigeeni: a, vietnam, 1203, 2004 (h5n1) - influenza, human; immunization; disease outbreaks - rokotteet - influenssan ennaltaehkäisy virallisesti ilmoitetussa pandemiatilanteessa. pandemian influenssarokote on käytettävä virallisten ohjeiden mukaisesti.
ditekipol injektioneste, suspensio
aj vaccines a/s - corynebacterium diphtheriae toxoid, adsorbed, poliovirus type 1 (brunhilde), inactivated, poliovirus type 3 (saukett), inactivated, bordetella pertussis toxoid, adsorbed, poliovirus type 2 (mef-1), inactivated, clostridium tetani toxoid, adsorbed - injektioneste, suspensio - kurkkumätä-
focetria
novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/california/7/2009 (h1n1)-derived strain used nymc x-181 - influenza, human; immunization; disease outbreaks - influenssarokot - a (h1n1v) 2009 -viruksen aiheuttaman influenssan profylaksia. focetria-rokotetta tulee käyttää virallisen ohjeistuksen mukaisesti.
pandemic influenza vaccine h5n1 astrazeneca (previously pandemic influenza vaccine h5n1 medimmune)
astrazeneca ab - (live attenuated) reassortant influenza virus (a / vietnam / 1203/2004 (h5n1) -kanta - influenssa, ihminen - rokotteet - influenssan ennaltaehkäisy virallisesti ilmoitetussa pandemiatilanteessa lapsilla ja nuorilla 12 kuukauden ikäisiltä alle 18-vuotiaille. pandemic influenza vaccine h5n1 astrazeneca tulee käyttää virallisen ohjeistuksen mukaisesti.
spikevax (previously covid-19 vaccine moderna)
moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - rokotteet - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.
vaxzevria (previously covid-19 vaccine astrazeneca)
astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - rokotteet - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older. käyttö tämä rokote tulee virallisten suositusten mukaisesti.